{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:32:53Z","timestamp":1788921173422,"version":"build-2803163510"},"reference-count":82,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) is associated with reduced functional capacity and quality of life, as well as with high rates of heart failure hospitalisation and mortality. Valvular heart disease (VHD) is frequently encountered in patients with HFpEF, and both conditions share common risk factors, such as age, hypertension, diabetes and coronary artery disease, which may contribute to their shared pathogenesis and progression. With recent advances in percutaneous therapies for VHD and an improved understanding of HFpEF, there is a growing interest in the relationship between VHD and HFpEF. In this review, we provide an overview of the pathophysiology, epidemiology and management strategies of tricuspid regurgitation, mitral regurgitation, aortic stenosis and aortic regurgitation in the setting of HFpEF.<\/jats:p>","DOI":"10.15420\/cfr.2025.13","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:01:17Z","timestamp":1779876077000},"source":"Crossref","is-referenced-by-count":1,"title":["Valvular Heart Disease in Heart Failure with Preserved Ejection Fraction"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4132-0388","authenticated-orcid":false,"given":"Athena","family":"Adeli","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"publisher"}],"name":"Karolinska Institutet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-1548","authenticated-orcid":false,"given":"Revathy","family":"Sampath-Kumar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4047-7730","authenticated-orcid":false,"given":"Anne","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"publisher"}],"name":"Karolinska Institutet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6617-2070","authenticated-orcid":false,"given":"Aristomenis","family":"Manouras","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"publisher"}],"name":"Karolinska Institutet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"publisher"}],"name":"Karolinska Institutet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1342-9191","authenticated-orcid":false,"given":"Rebecca T","family":"Hahn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01esghr10","id-type":"ROR","asserted-by":"publisher"}],"name":"Columbia University Irving Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-4482","authenticated-orcid":false,"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"publisher"}],"name":"Karolinska Institutet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5688-6101","authenticated-orcid":false,"given":"Bahira","family":"Shahim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"publisher"}],"name":"Karolinska Institutet"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref0","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID:\u00a034447992."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kapelios CJ, Shahim B, Lund LH, Savarese G. Epidemiology, clinical characteristics and cause-specific outcomes in heart failure with preserved ejection fraction. Card Fail Rev 2023;9:e14. https:\/\/doi.org\/10.15420\/cfr.2023.03; PMID:\u00a038020671.","DOI":"10.15420\/cfr.2023.03"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Hahn RT, Lindenfeld J, B\u00f6hm M, et al. Tricuspid regurgitation in patients with heart failure and preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2024;84:195\u2013212. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.047; PMID:\u00a038960514.","DOI":"10.1016\/j.jacc.2024.04.047"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Settergren C, Benson L, Shahim A, et al. Cause-specific death in heart failure across the ejection fraction spectrum: a comprehensive assessment of over 100\u2009000 patients in the Swedish Heart Failure Registry. Eur J Heart Fail 2024;26:1150\u20139. https:\/\/doi.org\/10.1002\/ejhf.3230; PMID:\u00a038606645.","DOI":"10.1002\/ejhf.3230"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Shahim B, Shahim A, Adamo M, et al. Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction. Eur J Heart Fail 2023;25:1049\u201360. https:\/\/doi.org\/10.1002\/ejhf.2908; PMID:\u00a037210639.","DOI":"10.1002\/ejhf.2908"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Fan Y, Lee APW. Valvular disease and heart failure with preserved ejection fraction. Heart Fail Clin 2021;17:387-95.https:\/\/doi.org\/10.1016\/j.hfc.2021.02.005; PMID:\u00a034051971.","DOI":"10.1016\/j.hfc.2021.02.005"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297\u2013317. https:\/\/doi.org\/10.1093\/eurheartj\/ehz641; PMID:\u00a031504452.","DOI":"10.1093\/eurheartj\/ehz641"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574-85. https:\/\/doi.org\/10.1002\/ejhf.813; PMID:\u00a028386917.","DOI":"10.1002\/ejhf.813"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Brennan JM, Petrescu M, McCarthy PM, et al. Contemporary prevalence of valvular heart disease & diagnostic variability across centers. J Am Coll Cardiol 2022;79(9 Suppl):1723. https:\/\/doi.org\/10.1016\/S0735-1097(22)02714-0.","DOI":"10.1016\/S0735-1097(22)02714-0"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Adamo M, Chioncel O, Benson L, et al. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: an analysis from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2023;25:1061\u201371. https:\/\/doi.org\/10.1002\/ejhf.2929; PMID: 37365841.","DOI":"10.1002\/ejhf.2929"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hamo CE, DeJong C, Hartshorne-Evans N, et al. Heart failure with preserved ejection fraction. Nat Rev Dis Primers 2024;10:55. https:\/\/doi.org\/10.1038\/s41572-024-00540-y; PMID:\u00a039143132.","DOI":"10.1038\/s41572-024-00540-y"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Gevaert AB, Kataria R, Zannad F, et al.Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart 2022;108:1342\u201350. https:\/\/doi.org\/10.1136\/heartjnl-2021-319605; PMID:\u00a035022210.","DOI":"10.1136\/heartjnl-2021-319605"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Riccardi M, Cikes M, Adamo M, et al. Functional mitral regurgitation and heart failure with preserved ejection fraction: clinical implications and management. J Card Fail 2024;30:929\u201339. https:\/\/doi.org\/10.1016\/j.cardfail.2024.02.024; PMID:\u00a038522637.","DOI":"10.1016\/j.cardfail.2024.02.024"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol 2022;19:100\u201316. https:\/\/doi.org\/10.1038\/s41569-021-00605-5; PMID:\u00a034489589.","DOI":"10.1038\/s41569-021-00605-5"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis.  JACC Heart Fail 2020;8:712\u201324. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.007; PMID:\u00a032653448.","DOI":"10.1016\/j.jchf.2020.04.007"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"van Heerebeek L, Hamdani N, Falc\u00e3o-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012;126:830\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.076075; PMID:\u00a022806632.","DOI":"10.1161\/CIRCULATIONAHA.111.076075"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Sanders-van Wijk S, Tromp J, Beussink-Nelson L, et al. Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study. Circulation 2020;142:2029\u201344. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.045810; PMID:\u00a033034202.","DOI":"10.1161\/CIRCULATIONAHA.120.045810"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 2018;39:3439\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehy531; PMID:\u00a030165580.","DOI":"10.1093\/eurheartj\/ehy531"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Chirinos JA, Orlenko A, Zhao L, et al. Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 2020;75:1281\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.069; PMID:\u00a032192654.","DOI":"10.1016\/j.jacc.2019.12.069"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Packer M, Lam CSP, Lund LH, et al. Characterization of the inflammatory\u2013metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail 2020;22:1551\u201367. https:\/\/doi.org\/10.1002\/ejhf.1902; PMID:\u00a032441863.","DOI":"10.1002\/ejhf.1902"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Venkateshvaran A, Faxen UL, Hage C, et al. Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS-HFpEF study. Eur J Heart Fail 2022;24:2251\u201360. https:\/\/doi.org\/10.1002\/ejhf.2709; PMID:\u00a036196462.","DOI":"10.1002\/ejhf.2709"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Obokata M, Reddy YNV, Pislaru SV, et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6-19. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026807; PMID:\u00a028381470.","DOI":"10.1161\/CIRCULATIONAHA.116.026807"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Fax\u00e9n J, Benson L, Mantel \u00c4, et al. Associations between rheumatoid arthritis, incident heart failure, and left ventricular ejection fraction. Am Heart J 2023;259:42\u201351. https:\/\/doi.org\/10.1016\/j.ahj.2023.02.001; PMID:\u00a036773746.","DOI":"10.1016\/j.ahj.2023.02.001"},{"key":"ref23","unstructured":"Chioncel O, Adamo M, Nikolaou M, et al.  Acute heart failure and valvular heart disease: a scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. Eur J Heart Fail 2023;25:1025\u201348. https:\/\/doi.org\/10.1002\/ejhf.2918; PMID:\u00a037312239."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: A report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 2023;81:1835\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.393; PMID:\u00a037137593.","DOI":"10.1016\/j.jacc.2023.03.393"},{"key":"ref25","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195; PMID: 37622666."},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022;400:757\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(22)01429-5; PMID:\u00a036041474.","DOI":"10.1016\/S0140-6736(22)01429-5"},{"key":"ref27","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1313731; PMID:\u00a024716680."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013;309:781\u201391. https:\/\/doi.org\/10.1001\/jama.2013.905; PMID:\u00a023443441.","DOI":"10.1001\/jama.2013.905"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024;391:1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107; PMID:\u00a039225278.","DOI":"10.1056\/NEJMe2410904"},{"key":"ref30","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609\u201320. https:\/\/doi.org\/10.1056\/nejmoa1908655; PMID: 31475794."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063; PMID:\u00a035363499.","DOI":"10.1161\/CIR.0000000000001073"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Dhont S, van den Acker G, van Loon T, et al. Mitral regurgitation in heart failure with preserved ejection fraction: the interplay of valve, ventricle, and atrium. Eur J Heart Fail 2024;26:974\u201383. https:\/\/doi.org\/10.1002\/ejhf.3231; PMID:\u00a038629747.","DOI":"10.1002\/ejhf.3231"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Tamargo M, Obokata M, Reddy YNV, et al. Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction. Eur J Heart Fail 2020;22:489\u201398. https:\/\/doi.org\/10.1002\/ejhf.1699; PMID:\u00a031908127.","DOI":"10.1002\/ejhf.1699"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Kajimoto K, Sato N, Takano T; Investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) Registry. Functional mitral regurgitation at discharge and outcomes in patients hospitalized for acute decompensated heart failure with a preserved or reduced ejection fraction. Eur J Heart Fail 2016;18:1051\u20139. https:\/\/doi.org\/10.1002\/ejhf.562; PMID: 27212582.","DOI":"10.1002\/ejhf.562"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Oikawa M, Yoshihisa A, Sato Y, et al. Prognostic impact of moderate mitral regurgitation on hospitalized heart failure patients with preserved ejection fraction: a report from the JASPER registry. Heart Vessels 2020;35:1087\u201394. https:\/\/doi.org\/10.1007\/s00380-020-01581-5; PMID:\u00a032193620.","DOI":"10.1007\/s00380-020-01581-5"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Shah AM, Cikes M, Prasad N, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2019;74:2858\u201373.https:\/\/doi.org\/10.1016\/j.jacc.2019.09.063; PMID:\u00a031806129.","DOI":"10.1016\/j.jacc.2019.09.063"},{"key":"ref37","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561\u2013632. https:\/\/doi.org\/10.1093\/ejcts\/ezac209; PMID:\u00a035352803."},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Praz F, Borger MA, Lanz J, et al. 2025 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2025;46:4635\u2013736. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf194; PMID:\u00a040878295.","DOI":"10.1093\/eurheartj\/ehag096"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Mascherbauer J, Zotter-Tufaro C, Duca F, et al. Wedge pressure rather than left ventricular end-diastolic pressure predicts outcome in heart failure with preserved ejection fraction. JACC Heart Fail 2017;5:795\u2013801. https:\/\/doi.org\/10.1016\/j.jchf.2017.08.005; PMID:\u00a029032138.","DOI":"10.1016\/j.jchf.2017.08.005"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Al-Sadawi M, Aleem S, Aslam F, et al. Rhythm versus rate control for atrial fibrillation in heart failure with preserved ejection fraction. Heart Rhythm 2022;3:520\u20135. https:\/\/doi.org\/10.1016\/j.hroo.2022.06.009; PMID: 36340484.","DOI":"10.1016\/j.hroo.2022.06.009"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Aldaas OM, Lupercio F, Darden D, et al. Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. Am J Cardiol 2021;142:66\u201373. https:\/\/doi.org\/10.1016\/j.amjcard.2020.11.039; PMID: 33290688.","DOI":"10.1016\/j.amjcard.2020.11.039"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018;379:2297\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1805374; PMID:\u00a030145927.","DOI":"10.1056\/NEJMoa1805374"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018;379:2307\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1806640; PMID:\u00a030280640.","DOI":"10.1056\/NEJMoa1806640"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Anker SD, Friede T, von Bardeleben RS, et al. Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation. N Engl J Med 2024;391:1799\u2013809. https:\/\/doi.org\/10.1056\/NEJMoa2314328; PMID:\u00a039216092.","DOI":"10.1056\/NEJMe2410896"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Lerakis S, Kini AS, Asch FM, et al. Outcomes of transcatheter mitral valve repair for secondary mitral regurgitation by severity of left ventricular dysfunction. EuroIntervention 2021;17:e335\u201342. https:\/\/doi.org\/10.4244\/EIJ-D-20-01265; PMID:\u00a033589408.","DOI":"10.4244\/EIJ-D-20-01265"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Claeys MJ, Debonnaire P, Bracke V, et al. Clinical and hemodynamic effects of percutaneous edge-to-edge mitral valve repair in atrial versus ventricular functional mitral regurgitation. Am J Cardiol 2021;161:70\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2021.08.062; PMID:\u00a034794621.","DOI":"10.1016\/j.amjcard.2021.08.062"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Feldman T, Foster E, Glower DD, et al.Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1009355; PMID:\u00a021463154.","DOI":"10.1056\/NEJMoa1009355"},{"key":"ref48","unstructured":"Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 2021;162:e183\u2013353. https:\/\/doi.org\/10.1016\/j.jtcvs.2021.04.002; PMID: 33972115."},{"key":"ref49","unstructured":"Baldus S, Doenst T, Pfister R, et al. Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation. N Engl J Med 2024;391:1787\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2408739; PMID:\u00a039216093."},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Talha KM, Metra M, Butler J. Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation. Eur Heart J 2024;45:4539\u201341. https:\/\/doi.org\/10.1093\/eurheartj\/ehae544; PMID:\u00a039250731.","DOI":"10.1093\/eurheartj\/ehae544"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Hahn RT, Zamorano JL. The need for a new tricuspid regurgitation grading scheme. Eur Heart J Cardiovasc Imaging 2017;18:1342\u20133. https:\/\/doi.org\/10.1093\/ehjci\/jex139; PMID:\u00a028977455.","DOI":"10.1093\/ehjci\/jex139"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611\u201344. https:\/\/doi.org\/10.1093\/ehjci\/jet105; PMID:\u00a023733442.","DOI":"10.1093\/ehjci\/jet105"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Hahn RT. Tricuspid regurgitation. N Engl J Med 2023;388:1876\u201391. https:\/\/doi.org\/10.1056\/NEJMra2216709; PMID:\u00a037195943.","DOI":"10.1056\/NEJMra2216709"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Bartko PE, Heitzinger G, Pavo N, et al. Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. BMJ 2021;373:n1421. https:\/\/doi.org\/10.1136\/bmj.n1421; PMID:\u00a034193442.","DOI":"10.1136\/bmj.n1421"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Omote K, Nagai T, Kamiya K, et al. Long-term prognostic significance of admission tricuspid regurgitation pressure gradient in hospitalized patients with heart failure with preserved ejection fraction: a report from the Japanese real-world multicenter registry. J Card Fail 2019;25:978\u201385. https:\/\/doi.org\/10.1016\/j.cardfail.2019.07.010; PMID:\u00a031344403.","DOI":"10.1016\/j.cardfail.2019.07.010"},{"key":"ref56","unstructured":"Zack CJ, Fender EA, Chandrashekar P, et al. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol 2017;70:2953\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2017.10.039; PMID:\u00a029241483."},{"key":"ref57","unstructured":"Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol 2019;74:2998\u20133008. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.028; PMID: 31568868."},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med 2023;388:1833\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2300525; PMID:\u00a036876753.","DOI":"10.1056\/NEJMoa2300525"},{"key":"ref59","unstructured":"Kar S, Makkar RR, Whisenant BK, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: the TRILUMINATE pivotal randomized controlled trial. Circulation 2025;151:1630\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.074536; PMID:\u00a040159089."},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Metra M, Tomasoni D, Adamo M, et al. Evidence generation and implementation of transcatheter interventions for atrioventricular valvular heart disease in heart failure: current status and future directions. Circulation 2025;151:1342\u201363. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.070411; PMID:\u00a040324027.","DOI":"10.1161\/CIRCULATIONAHA.124.070411"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Chopra V, Khan MS, Abdelhamid M, et al. iCARDIO alliance global implementation guidelines on heart failure 2025. Heart Lung Circ 2025;34:e55\u201382. https:\/\/doi.org\/10.1016\/j.hlc.2025.05.094; PMID: 40533340.","DOI":"10.1016\/j.hlc.2025.09.010"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Biase N, Mazzola M, Del Punta L, et al. Haemodynamic and metabolic phenotyping of patients with aortic stenosis and preserved ejection fraction: a specific phenotype of heart failure with preserved ejection fraction? Eur J Heart Fail 2023;25:1947\u201358. https:\/\/doi.org\/10.1002\/ejhf.3018; PMID:\u00a037655676.","DOI":"10.1002\/ejhf.3018"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Krittanawong C, Kumar A, Wang Z, et al. Predictors of in-hospital mortality after transcatheter aortic valve implantation. Am J Cardiol 2020;125:251\u20137.https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.014; PMID:\u00a031759517.","DOI":"10.1016\/j.amjcard.2019.10.014"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Ishizu K, Shirai S, Isotani A, et al. Long-term prognostic value of the H2FPEF score in patients undergoing transcatheter aortic valve implantation. ESC Heart Fail 2024;11:2159\u201371. https:\/\/doi.org\/10.1002\/ehf2.14773; PMID:\u00a038607328.","DOI":"10.1002\/ehf2.14773"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Akao K, Imamura T, Tanaka S, et al. Prognostic impact of modified H2FPEF score in patients receiving trans-catheter aortic valve replacement. J Clin Med 2023;12:5396. https:\/\/doi.org\/10.3390\/jcm12165396; PMID:\u00a037629434.","DOI":"10.3390\/jcm12165396"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Vaikunth SS, Lui GK. Heart failure with reduced and preserved ejection fraction in adult congenital heart disease. Heart Fail Rev 2020;25:569\u201381. https:\/\/doi.org\/10.1007\/s10741-019-09904-z; PMID: 31873841.","DOI":"10.1007\/s10741-019-09904-z"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Venema CS, van Bergeijk KH, Krikken JA, et al. Heart failure with preserved ejection fraction phenotype is associated with early symptom onset in aortic stenosis and residual symptoms after transcatheter aortic valve implantation. J Am Heart Assoc 2025;14:e038786. https:\/\/doi.org\/10.1161\/JAHA.124.038786; PMID: 40240943.","DOI":"10.1161\/JAHA.124.038786"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Hoedemakers S, Verwerft J, Reddy YNV, et al. Cardiac dysfunction rather than aortic valve stenosis severity drives exercise intolerance and adverse haemodynamics. Eur Heart J Cardiovasc Imaging 2024;25:302\u201312. https:\/\/doi.org\/10.1093\/ehjci\/jead276; PMID: 37875135.","DOI":"10.1093\/ehjci\/jead276"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"De Vecchis R, Di Biase G, Esposito C, et al. Statin use for nonrheumatic calcific aortic valve stenosis: a review with meta-analysis. J Cardiovasc Med (Hagerstown) 2013;14:559\u201367. https:\/\/doi.org\/10.2459\/JCM.0b013e3283587267; PMID: 23032960.","DOI":"10.2459\/JCM.0b013e3283587267"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Rodriguez-Gabella T, Catal\u00e1 P, Mu\u00f1oz-Garc\u00eda AJ, et al. Renin\u2013angiotensin system inhibition following transcatheter aortic valve replacement. J Am Coll Cardiol 2019;74:631\u201341. https:\/\/doi.org\/10.1016\/j.jacc.2019.05.055; PMID: 31370954.","DOI":"10.1016\/j.jacc.2019.05.055"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Goel SS, Kleiman NS, Zoghbi WA, et al. Renin\u2013angiotensin system blockade in aortic stenosis: implications before and after aortic valve replacement. J Am Heart Assoc 2020;9:e016911. https:\/\/doi.org\/10.1161\/JAHA.120.016911; PMID: 32893727.","DOI":"10.1161\/JAHA.120.016911"},{"key":"ref72","unstructured":"Raposeiras-Roubin S, Amat-Santos IJ, Rossello X, et al. Dapagliflozin in patients undergoing transcatheter aortic-valve implantation. N Engl J Med 2025;392:1396\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2500366; PMID: 40162639."},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Kvidal P, Bergstr\u00f6m R, H\u00f6rte LG, St\u00e5hle E. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol 2000;35:747\u201356. https:\/\/doi.org\/10.1016\/S0735-1097(99)00584-7; PMID:\u00a010716479.","DOI":"10.1016\/S0735-1097(99)00584-7"},{"key":"ref74","unstructured":"Murphy ES, Lawson RM, Starr A, Rahimtoola SH. Severe aortic stenosis in patients 60 years of age or older: left ventricular function and 10-year survival after valve replacement. Circulation 1981;64:II184\u20138. PMID: 7249320."},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2 \u2013 isolated valve surgery. Ann Thorac Surg 2009;88(Suppl):S23\u201342.  https:\/\/doi.org\/10.1016\/j.athoracsur.2009.05.056; PMID:\u00a019559823.","DOI":"10.1016\/j.athoracsur.2009.05.056"},{"key":"ref76","unstructured":"Makkar RR, Thourani VH, Mack MJ, et al.Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382:799\u2013809. https:\/\/doi.org\/10.1056\/NEJMoa1910555; PMID:\u00a031995682."},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Peigh G, Puthumana JJ, Bonow RO. Aortic regurgitation and heart failure: advances in diagnosis, management, and interventions. Heart Fail Clin 2023;19:285\u201396. https:\/\/doi.org\/10.1016\/j.hfc.2023.02.007; PMID:\u00a037230644.","DOI":"10.1016\/j.hfc.2023.02.007"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"De Colle C, Paolisso P, Gallinoro E, et al. Association of mild-to-moderate aortic regurgitation with outcomes in heart failure with preserved ejection fraction. Mayo Clin Proc 2023;98:1469\u201381. https:\/\/doi.org\/10.1016\/j.mayocp.2023.06.017; PMID:\u00a037793725.","DOI":"10.1016\/j.mayocp.2023.06.017"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Galusko V, Thornton G, Jozsa C, et al. Aortic regurgitation management: a systematic review of clinical practice guidelines and recommendations. Eur Heart J Qual Care Clin Outcomes 2022;8:113\u201326. https:\/\/doi.org\/10.1093\/ehjqcco\/qcac001; PMID:\u00a035026012.","DOI":"10.1093\/ehjqcco\/qcac001"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Takagi H, Hari Y, Kawai N, et al. Meta-analysis and meta-regression of transcatheter aortic valve implantation for pure native aortic regurgitation. Heart Lung Circ 2020;29:729\u201341. https:\/\/doi.org\/10.1016\/j.hlc.2019.04.012; PMID: 31133516.","DOI":"10.1016\/j.hlc.2019.04.012"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 2018;391:572\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(17)32520-5; PMID: 29174292.","DOI":"10.1016\/S0140-6736(17)32520-5"}],"container-title":["Cardiac Failure Review"],"original-title":[],"link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:01:35Z","timestamp":1779876095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":82,"URL":"https:\/\/doi.org\/10.15420\/cfr.2025.13","relation":{},"ISSN":["2057-7540","2057-7559"],"issn-type":[{"value":"2057-7540","type":"print"},{"value":"2057-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"article-number":"e14"}}